Aktieanalys

Ultimovacs: UV1-103 data keeps shaping up nicely - Redeye

{newsItem.title}

Redeye Publicerad: 07 Oct 2022 10:56

Redeye comments on Ultimovacs reporting a three-year survival OS rate of some 71% for cohort 1 of its UV1-103 study. We positively view the study data continuing to shape up nicely relative to historical controls and nudge up our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/857346/ultimovacs-uv1-103-data-keeps-shaping-up-nicely?utm_source=finwire&utm_medium=RSS

Nyheter om Zelluna

Läses av andra just nu

Om aktien Zelluna

Senaste nytt